GENinCode has reported interim results for the six months to June 2023, noting revenues up 43% YoY and strong mix-driven gross margin improvement. Increased headcount to support commercialisation saw an increase in adjusted EBITDA loss for the period. We believe the company is making strong commercial progress across all three regions and notably has 40 US institutions onboarded for the Early Access Programme, highlighting the potential for GENinCode’s lead products in the US. Cash at the end of ....
